Sichuan Kelun Pharmaceutical Co.,Ltd. clinical trials

The registry lists 65 studies whose lead sponsor is Sichuan Kelun Pharmaceutical Co.,Ltd. or one of 3 companies grouped under it. 40 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 21, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 65. Browse all 65 →

• SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid TumorsRecruitingNCT06726369Phase 1

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI FailureNot yet recruitingNCT07854509Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of KL0011034 Injection Administered by Continuous Infusion in Healthy Adult SubjectsNot yet recruitingNCT07828470Phase 1

  Sponsor listed in the registry: Hunan Kelun Pharmaceutical Co., Ltd. · First submitted after Hunan Kelun Pharmaceutical Co., Ltd. became part of Sichuan Kelun Pharmaceutical Co.,Ltd.

• SKB118 Injection in Advanced Solid TumorsRecruitingNCT07586943Phase 1/2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Randomized, Phase Ib, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SKB575 (HBM7575) in Participants With AsthmaRecruitingNCT07732023Phase 1

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Multicenter, Open-label, Phase II Umbrella Study to Evaluate the Efficacy and Safety of the Investigational Product in Participants With Advanced or Metastatic Pancreatic CancerNot yet recruitingNCT07814066Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC ParticipantsRecruitingNCT07668154Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• SKB565 for Injection in Advanced Solid TumorsRecruitingNCT07545265Phase 1/2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT07622186Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerRecruitingNCT07329322Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• Study of SKB103 in HER2-negative Breast CancerNot yet recruitingNCT07774624Phase 1/2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic CarcinomaRecruitingNCT07324629Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• SKB264 in Combination With SKB118 for Non-Small Cell Lung CancerRecruitingNCT07697586Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of SKB571 in Participants With Gastrointestinal TumorsRecruitingNCT07564466Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET AbnormalitiesRecruitingNCT07308106Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting Injection Following a Single Administration in Healthy Subjects/Patients With Schizophrenia.RecruitingNCT06674694Phase 1
• A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KL0011034 Injection in Healthy VolunteersRecruitingNCT07474545Phase 1

  Sponsor listed in the registry: Hunan Kelun Pharmaceutical Co., Ltd. · First submitted after Hunan Kelun Pharmaceutical Co., Ltd. became part of Sichuan Kelun Pharmaceutical Co.,Ltd.

• SKB315 in Combination Therapy in Patients With Advanced or Metastatic GC/ GEJ AdenocarcinomaNot yet recruitingNCT07609667Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Phase I Study of KLA318-2 Nanocrystal InjectionRecruitingNCT07171034Phase 1

  Sponsor listed in the registry: Hunan Kelun Pharmaceutical Co., Ltd. · First submitted after Hunan Kelun Pharmaceutical Co., Ltd. became part of Sichuan Kelun Pharmaceutical Co.,Ltd.

• Single-dose,First-in-human of KLA478RecruitingNCT07240675Phase 1

  Sponsor listed in the registry: Hunan Kelun Pharmaceutical Co., Ltd. · First submitted after Hunan Kelun Pharmaceutical Co., Ltd. became part of Sichuan Kelun Pharmaceutical Co.,Ltd.

• First-in-Human Single and Multiple Dose of KLA578-1 for InjectionRecruitingNCT07143318Phase 1

  Sponsor listed in the registry: Hunan Kelun Pharmaceutical Co., Ltd. · First submitted after Hunan Kelun Pharmaceutical Co., Ltd. became part of Sichuan Kelun Pharmaceutical Co.,Ltd.

• SKB103 for Injection in Advanced Solid TumorsRecruitingNCT07459998Phase 1/2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.RecruitingNCT05351788Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Phase II Study of SKB571 in Patients With Lung CancerRecruitingNCT07230405Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant TumorsRecruitingNCT07448922Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of SKB518 in Patients With Advanced Solid TumorsRecruitingNCT06428331Phase 1

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid TumorsRecruitingNCT06736327Phase 1

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of SKB315 in Patients With Advanced Solid TumorsRecruitingNCT05367635Phase 1

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Phase 1 Study of SKB571 in Subjects With Advanced Solid TumorsRecruitingNCT06725381Phase 1

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast CancerRecruitingNCT06081959Phase 3

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• SKB445 for Injection in Solid TumorsRecruitingNCT06826040Phase 1

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of SKB518 in Patients With Lung CancerRecruitingNCT07019675Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• SKB105 for Injection in Advanced Solid TumorsRecruitingNCT07380386Phase 1/2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis ParticipantsRecruitingNCT07488065Phase 1

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of SKB107 in Advanced Solid Tumors With Bone MetastasesRecruitingNCT07087197Phase 1

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine TherapyRecruitingNCT07071337Phase 3

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• SKB500 Combinations in Patients With Small Cell Lung CancerRecruitingNCT07296809Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast CancerRecruitingNCT07299825Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Phase I Clinical Study of a Single Dose of KLA480RecruitingNCT07030790Phase 1

  Sponsor listed in the registry: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

• A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast CancerActive, not recruitingNCT06279364Phase 3

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of A166 in Patients With Advanced Solid Malignant TumorsCompletedNCT05311397Phase 1

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study Evaluating the Drug-Drug Interaction Between KL0011034 Injection and Alfentanil Hydrochloride InjectionCompletedNCT07710560Phase 1

  Sponsor listed in the registry: Hunan Kelun Pharmaceutical Co., Ltd. · First submitted after Hunan Kelun Pharmaceutical Co., Ltd. became part of Sichuan Kelun Pharmaceutical Co.,Ltd.

• SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast CancerCompletedNCT05445908Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• SKB410 for Injection in Solid TumorsCompletedNCT05906537Phase 1

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerActive, not recruitingNCT06670196Phase 3

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerActive, not recruitingNCT06711900Phase 3

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OCActive, not recruitingNCT07341100Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• Bioequivalence Study of Gefitinib Tablets Under Fasting ConditionsCompletedNCT03050164Phase 1

  Sponsor listed in the registry: Hunan Kelun Pharmaceutical Co., Ltd. · First submitted after Hunan Kelun Pharmaceutical Co., Ltd. became part of Sichuan Kelun Pharmaceutical Co.,Ltd.

• Bioequivalence Study of Gefitinib Tablets Under Fed ConditionsCompletedNCT03050177Phase 1

  Sponsor listed in the registry: Hunan Kelun Pharmaceutical Co., Ltd. · First submitted after Hunan Kelun Pharmaceutical Co., Ltd. became part of Sichuan Kelun Pharmaceutical Co.,Ltd.